<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981198</url>
  </required_header>
  <id_info>
    <org_study_id>Soliton 2018-001</org_study_id>
    <nct_id>NCT03981198</nct_id>
  </id_info>
  <brief_title>Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite</brief_title>
  <official_title>Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) Nov Heavy Device for the Treatment of Cellulite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soliton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soliton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility study is to evaluate the safety, tolerability and efficacy of Soliton's Rapid&#xD;
      Acoustic Pulse (RAP) device for the treatment of cellulite&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability of Soliton's RAP Nov Heavy for the treatment of&#xD;
      cellulite. To assess the efficacy of Soliton's RAP Nov Heavy device for the temporary&#xD;
      improvement in appearance of cellulite in terms of mean change in cellulite severity score&#xD;
      (CSS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>18 weeks</time_frame>
    <description>The primary safety endpoint will be met if all treated Participants are free from serious adverse events (SAEs) attributable to the RAP device immediately post treatment and at the 3-month follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Tolerability</measure>
    <time_frame>18 Weeks</time_frame>
    <description>The primary endpoint will be met if a mean tolerability measure using pain scores averaged across all treated Participants is &lt; 8.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellulite improvement</measure>
    <time_frame>18 weeks</time_frame>
    <description>A ≥15% mean reduction in the 0-5-point Cellulite Severity Scale as determined by physician assessment of Participant photographs taken before and 3 months after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>RAP treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soliton Rapid Acoustic Pulse (RAP)</intervention_name>
    <description>Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.</description>
    <arm_group_label>RAP treatment</arm_group_label>
    <other_name>RAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female ages 18-65 years&#xD;
&#xD;
          -  Participant seeking treatment of cellulite in the upper lateral thigh areas&#xD;
&#xD;
          -  Participant presenting with cellulite Grade I or II on both thighs as graded using the&#xD;
             Nurnberger-Muller scale classification (Appendix A)&#xD;
&#xD;
          -  Participant has stable weight. Body Mass Index (B.M.I.) is ≤ 30&#xD;
&#xD;
          -  Participant will not have any other cellulite treatments for 12 months before and&#xD;
             throughout the 3-month follow-up&#xD;
&#xD;
          -  Participant is willing to participate in study and adhere to follow-up schedule&#xD;
&#xD;
          -  Participant is able to read and comprehend English&#xD;
&#xD;
          -  Participant has completed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is pregnant or planning to become pregnant during the duration of the&#xD;
             study&#xD;
&#xD;
          -  Participant has a BMI &gt; 30&#xD;
&#xD;
          -  Greater than 10% increase or decrease in body weight within past 6 months&#xD;
&#xD;
          -  Cellulite treatment on the thighs or buttocks in the last 12 months (Topical or&#xD;
             non-invasive procedure)&#xD;
&#xD;
          -  Metal or plastic implants in the area of the treatment (vascular stent, or implants in&#xD;
             the hips, knees, etc.)&#xD;
&#xD;
          -  Active electronic implants such as pacemakers, defibrillators, cochlear implants,&#xD;
             nerve/brain stimulators, drug pump, etc.&#xD;
&#xD;
          -  Prior liposuction in the thighs or buttocks or any other invasive procedure to limit&#xD;
             cellulite.&#xD;
&#xD;
          -  Medical disorder that would hinder the wound healing or immune response (no blood&#xD;
             disorder, diabetes, inflammatory disease, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher C Capelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Soliton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

